Using a Recurrent Neural Network To Inform the Use of Prostate- specific Antigen (PSA) and PSA Density for Dynamic Monitoring of the Risk of Prostate Cancer Progression on Active Surveillance

EUROPEAN UROLOGY OPEN SCIENCE. 2023. Vol. 52. P. 36–39.

Sushentsev N., Abrego L., Colarieti A., Sanmugalingam N., Stanzione A., Zawaideh J. P., Caglic I., Zaikin A., Blyuss O.

The global uptake of prostate cancer (PCa) active surveillance (AS) is steadily increasing. While prostate-specific antigen density (PSAD) is an important baseline predictor of PCa progression on AS, there is a scarcity of recommendations on its use in follow-up. In particular, the best way of measuring PSAD is unclear. One approach would be to use the baseline gland volume (BGV) as a denominator in all calculations throughout AS (nonadaptive PSAD, PSADNA), while another would be to remeasure gland volume at each new magnetic resonance imaging scan (adaptive PSAD, PSADA). In addition, little is known about the predictive value of serial PSAD in comparison to PSA. We applied a long short-term memory recurrent neural network to an AS cohort of 332 patients and found that serial PSADNA significantly outperformed both PSADA and PSA for follow-up prediction of PCa progression because of its high sensitivity. Importantly, while PSADNA was superior in patients with smaller glands (BGV 55 ml), serial PSA was better in men with larger prostates of >55 ml.

Keywords: Longitudinal data, recurrent neural networks, prostate cancer, artificial intelligence, predictive modelling, Active surveillance, Prostate-specific antigen